Medtronic plc (MDT) FY2024 Annual P&L / Income Statement

Revenue by Business Segment by Subsegment

2023-04-29 to 2024-04-26

Swipe to see the full flow
Medtronic plc (MDT) FY2024 Annual P&L / Income StatementIncome statement for 2023-04-29 through 2024-04-26. View: Segments by Subsegments. Revenue uses this breakdown; costs and expenses retain the consolidated categories.SOURCESREVENUEGROSSOPERATINGPRE-TAXNETMedical Surgical - Surgical & EndoscopyCardiovascular - Cardiac Rhythm & Heart FailureNeuroscience - Cranial & Spinal TechnologiesCardiovascular - Structural Heart & AorticNeuroscience - Specialty TherapiesDiabetesCardiovascular - Coronary & Peripheral VascularMedical Surgical - Acute Care & MonitoringNeuroscience - NeuromodulationUndisclosed (calculated)Other operating segmentNet salesGross profit (calculated)Cost of products sold, excluding amortization of intangible assetsOperating profitOperating costs, including other operating expenses (calculated)Selling, general, and administrative expenseResearch and development expenseAmortization of intangible assetsRestructuring charges, netCertain litigation charges, netOther operating expense (income), netIncome before income taxesOther income (expense), net (calculated)Net incomeIncome tax provisionGross profit (calculated)Gross profit(calculated)$21.15 BNet salesNet sales$32.36 BOperating profitOperating profit$5.14 BIncome before income taxesPretax income$4.84 BNet incomeNet income$3.71 BMedical Surgical - Surgical & EndoscopyMedical Surgical -Surgical & Endoscopy$6.51 BOperating costs, including other operating expenses (calculated)Operating costs(calculated)$16.00 BCardiovascular - Cardiac Rhythm & Heart FailureCardiovascular - CardiacRhythm & Heart Failure$6.00 BIncome tax provisionIncome taxes$1.13 BOther income (expense), net (calculated)Other income,net (calculated)−$307.00 MSelling, general, and administrative expenseSelling, general, andadministrative expense$10.74 BNeuroscience - Cranial & Spinal TechnologiesNeuroscience - Cranial& Spinal Technologies$4.76 BCost of products sold, excluding amortization of intangible assetsCost of products sold$11.22 BCardiovascular - Structural Heart & AorticCardiovascular -Structural Heart & Aortic$3.36 BResearch and development expenseResearch anddevelopment expense$2.74 BNeuroscience - Specialty TherapiesNeuroscience - Specialty Therapies$2.91 BAmortization of intangible assetsAmortization of intangible assets$1.69 BDiabetesDiabetes$2.49 BRestructuring charges, netRestructuring charges, net$226.00 MCardiovascular - Coronary & Peripheral VascularCardiovascular - Coronary& Peripheral Vascular$2.48 BCertain litigation charges, netCertain litigation charges, net$149.00 MOther operating expense (income), netOther operatingexpense (income), net$464.00 MMedical Surgical - Acute Care & MonitoringMedical Surgical - AcuteCare & Monitoring$1.91 BNeuroscience - NeuromodulationNeuroscience - Neuromodulation$1.75 BUndisclosed (calculated)Undisclosed (calculated)$1.00 MOther operating segmentOther operating segment$221.00 M
Chart details

Medtronic plc (MDT) FY2024 Annual P&L / Income Statement

Income statement for 2023-04-29 through 2024-04-26. View: Segments by Subsegments. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

Net sales
32,364,000,000 US dollars
Cost of products sold, excluding amortization of intangible assets
11,216,000,000 US dollars
Gross profit (calculated)
21,148,000,000 US dollars
Operating costs, including other operating expenses (calculated)
16,003,000,000 US dollars
Operating profit
5,144,000,000 US dollars
Other income (expense), net (calculated)
negative 307,000,000 US dollars
Income before income taxes
4,837,000,000 US dollars
Income tax provision
1,133,000,000 US dollars
Net income
3,705,000,000 US dollars
Diabetes
2,488,000,000 US dollars
Other operating segment
221,000,000 US dollars
Cardiovascular - Cardiac Rhythm & Heart Failure
5,995,000,000 US dollars
Cardiovascular - Coronary & Peripheral Vascular
2,478,000,000 US dollars
Cardiovascular - Structural Heart & Aortic
3,358,000,000 US dollars
Medical Surgical - Acute Care & Monitoring
1,908,000,000 US dollars
Medical Surgical - Surgical & Endoscopy
6,508,000,000 US dollars
Neuroscience - Cranial & Spinal Technologies
4,756,000,000 US dollars
Neuroscience - Neuromodulation
1,746,000,000 US dollars
Neuroscience - Specialty Therapies
2,905,000,000 US dollars
Undisclosed (calculated)
1,000,000 US dollars
Research and development expense
2,735,000,000 US dollars
Selling, general, and administrative expense
10,736,000,000 US dollars
Amortization of intangible assets
1,693,000,000 US dollars
Restructuring charges, net
226,000,000 US dollars
Certain litigation charges, net
149,000,000 US dollars
Other operating expense (income), net
464,000,000 US dollars

Chart connections

  • Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
  • Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.
  • The amounts that make up operating profit come to $5,145.00 M and operating profit is $5,144.00 M; the $1.00 M difference is within the rounding of the filed amounts.
  • The amounts that make up net income come to $3,704.00 M and net income is $3,705.00 M; the $1.00 M difference is within the rounding of the filed amounts.
Medtronic plc (MDT) FY2024 Annual P&L / Income Statement Sankey chart, Segments by Subsegments view
Free to share unchanged, with credit to Plicit.ai · CC BY-NC-ND 4.0Download PNG

Gross margin

65.3%

Gross profit / revenue

Operating margin

15.9%

Operating profit / revenue

Cash conversion

183.2%

Operating cash / net income, same period

Newsletter

Get the teardowns by email

Subscribe if you want the public-company teardowns in your inbox when they're released.

Product waitlist

Health Check and Teardown for your own company

A health check uncovers insights of your private books, not a public ticker. Join this list to get notified as soon as we go-live!